OTIC - Otonomy, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Otonomy, Inc.

4796 Executive Drive
San Diego, CA 92121
United States
619-323-2200
http://www.otonomy.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Dr. Jay B. LichterCo-Founder & Chairman60kN/A1962
Dr. David Allen WeberPres, CEO & Director874.94kN/A1960
Mr. Paul E. CayerChief Financial & Bus. Officer554.76kN/A1962
Mr. Robert Michael Savel IIChief Technical Officer498.5kN/A1968
Dr. Allen F. Ryan Ph.D.Co-Founder and Member of the Advisory PanelN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, a sustained-exposure formulation of small molecule otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Corporate Governance

Otonomy, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.